Dark

NBIX
Neurocrine Biosciences Inc
stock NASDAQ

Market Open

Jun 9, 2025 2:18:39 PM EDT

125.86USD+0.371%(+0.47)324,161

125.25Bid 125.58Ask 0.33Spread

Pre-market

Jun 4, 2025 8:00:30 AM EDT

125.00USD-0.311%(-0.39)0

After-hours

Jun 6, 2025 4:00:30 PM EDT

125.39USD+0.016%(+0.02)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

04:01PM EST Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter PR Newswire

Jan 20, 2022

09:55AM EST Barclays Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $100 Benzinga

Jan 18, 2022

06:47AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

06:44AM EST RBC Capital Downgrades Neurocrine Biosciences to Sector Perform, Lowers Price Target to $90 Benzinga

Jan 12, 2022

08:06AM EST Xenon Pharma Reports Collab With Neurocrine Biosciences To Develop Treatments For Epilepsy Reached Regulatory Milestone, Triggering $15M Payment To Xenon Benzinga

Jan 7, 2022

04:25PM EST Analyst Ratings For Neurocrine Biosciences Benzinga

01:07PM EST Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $103 Benzinga

01:03PM EST The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs Benzinga

Jan 6, 2022

04:04PM EST Neurocrine Biosciences Sees Q4 2021 INGREZZA Revenue ~$301M Benzinga

04:01PM EST Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 PR Newswire

Jan 3, 2022

04:35PM EST Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences, Sotera Health, Eagle Pharma Benzinga

04:12PM EST Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences Benzinga

04:03PM EST Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights Benzinga

04:01PM EST Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare PR Newswire

Dec 10, 2021

01:42PM EST Spruce Biosciences Wins Patent Trial Related To Tildacerfont Patent As Post Grant Review Filed By Neurocrine Biosciences Was Not Instituted Benzinga

Dec 8, 2021

11:24AM EST Expert Ratings For Neurocrine Biosciences Benzinga

10:25AM EST Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $154 Benzinga

08:37AM EST Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $129 Benzinga

08:19AM EST The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom Benzinga

07:59AM EST 'Did you know Biogen $BIIB put together a plan to acquire Neurocrine Biosciences $NBIX in 2019? Well, now you do! We take you inside the thwarted M&A plan, and how it was seen as a vote of no confidence in Vounatsos.' -STAT's Adam Feuerstein Benzinga

Dec 7, 2021

04:36PM EST Neurocrine Biosciences Announces Phase 3 Data For KINECT-HD Study Evaluating Valbenazine For Chorea Associated With Huntington Disease Benzinga

04:35PM EST Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study PR Newswire

Nov 30, 2021

04:07PM EST Neurocrine Biosciences Appoints Jude Onyia As Chief Scientific Officer RTTNews

04:06PM EST Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer PR Newswire

Nov 22, 2021

12:58PM EST Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets Benzinga

08:56AM EST Neurocrine Biosciences Inc. (NBIX) and Sosei Group said that they have signed a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders. RTTNews

08:09AM EST Neurocrine Biosciences And Sosei Heptares Announce Collaboration To Develop Novel Muscarinic Receptor Agonists For Schizophrenia And Other Neuropsychiatric Disorders Benzinga

08:03AM EST Neurocrine And Sosei To Develop Muscarinic Receptor Agonists For Schizophrenia And Other Neuropsychiatric Disorders RTTNews

08:01AM EST Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders PR Newswire

Nov 19, 2021

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

05:30AM EST BMO Capital Initiates Coverage On Neurocrine Biosciences with Underperform Rating, Announces Price Target of $76 Benzinga

Nov 17, 2021

12:09PM EST Analyst Ratings For Neurocrine Biosciences Benzinga

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 Benzinga

04:57AM EST JP Morgan Upgrades Neurocrine Biosciences to Overweight, Announces $124 Price Target Benzinga

Nov 9, 2021

04:01PM EST Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire

Nov 2, 2021

12:18PM EDT What 5 Analyst Ratings Have To Say About Neurocrine Biosciences Benzinga

10:56AM EDT Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $103 Benzinga

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:50AM EDT RBC Capital Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $119 Benzinga

10:50AM EDT Raymond James Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $150 Benzinga

10:27AM EDT Neurocrine Biosciences: Q3 Earnings Insights Benzinga

10:22AM EDT Neurocrine Biosciences Q3 EPS $0.64 Beats $0.60 Estimate, Sales $296.00M Miss $297.65M Estimate Benzinga

08:19AM EDT 08:18 Tuesday, November 2, 2021William Blair (RTTNews) - William Blair Reiterates Neurocrine Biosciences Inc (NBIX) At Outperform RTTNews

Nov 1, 2021

04:04PM EDT Neurocrine Biosciences Q3 EPS $0.23 Vs. Loss $0.62 Year Ago RTTNews

04:02PM EDT Neurocrine Biosciences Reports Third Quarter 2021 Financial Results PR Newswire

12:05PM EDT Neurocrine Biosciences's Return On Capital Employed Overview Benzinga

08:19AM EDT Neurocrine Biosciences Presents New INGREZZA Data At Psych Congress 2021 Benzinga

08:02AM EDT Neurocrine Biosciences Presents New INGREZZA(r) (valbenazine) Data at Psych PR Newswire

08:02AM EDT Neurocrine Biosciences Presents New INGREZZA Data At Psych Congress 2021 RTTNews

04:01AM EDT Earnings Scheduled For November 1, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 16, 2021

05:00PM EDT (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting PR Newswire

Oct 14, 2021

11:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 Benzinga

05:56AM EDT Morgan Stanley Downgrades Neurocrine Biosciences to Equal-Weight, Announces $112 Price Target Benzinga

Oct 11, 2021

04:01PM EDT Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter PR Newswire

Oct 8, 2021

07:30AM EDT World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic PR Newswire

Sep 10, 2021

09:54AM EDT Neurocrine Biosciences Inc.(NBIX) said that it will present new data from its movement disorder treatments for tardive dyskinesia or TD and Parkinson's disease at the International Parkinson and Movement Disorder Society's or MDS Virtual Congress 2021 being held September 17-22, 2021. RTTNews

09:26AM EDT Neurocrine Biosciences To Present New INGREZZA And ONGENTYS Data At MDS Virtual Congress 2021 RTTNews

09:25AM EDT Neurocrine Biosciences To Present New INGREZZA (valbenazine) And ONGENTYS (opicapone) Data At MDS Virtual Congress 2021 Benzinga

09:24AM EDT Neurocrine Biosciences to Present New INGREZZA(r) (valbenazine) and ONGENTYS(r) PR Newswire

Sep 8, 2021

08:35AM EDT Xenon Pharmaceuticals Announces Epilepsy Collaboration With Neurocrine Biosciences AChieved Regulatory Milestone, Triggering $10M Payment To Co. Benzinga

08:30AM EDT Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone with the approval of a clinical trial application (CTA) in Europe, triggering an aggregate payment of $10.0 million to Xenon. GlobeNewswire Inc

Sep 2, 2021

04:13PM EDT Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire

Aug 20, 2021

01:50PM EDT Looking into Neurocrine Biosciences's Return on Capital Employed Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 6, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021 Benzinga

08:44AM EDT Canaccord Genuity Downgrades Neurocrine Biosciences to Hold, Lowers Price Target to $108 Benzinga

Aug 5, 2021

04:44PM EDT Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease Benzinga

04:01PM EDT Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD PR Newswire

Aug 4, 2021

09:18AM EDT Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $110 Benzinga

Aug 3, 2021

04:17PM EDT Neurocrine Biosciences Q2 EPS $0.63 Beats $0.49 Estimate, Sales $288.90M Beat $274.38M Estimate Benzinga

04:11PM EDT Neurocrine Biosciences Inc (NBIX) released a profit for second quarter that decreased from the same period last year. RTTNews

04:05PM EDT Neurocrine Biosciences Q2 EPS $0.43 Vs. $0.81 Year Ago RTTNews

04:02PM EDT Neurocrine Biosciences Reports Second Quarter 2021 Financial Results PR Newswire

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Jul 19, 2021

04:01PM EDT Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter PR Newswire

Jul 8, 2021

04:01PM EDT Neurocrine Biosciences to Participate at the William Blair Biotech Focus PR Newswire

Jun 1, 2021

04:01PM EDT Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global PR Newswire

May 18, 2021

12:16PM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021 Benzinga

May 11, 2021

04:01PM EDT Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference PR Newswire

May 6, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021 Benzinga

08:48AM EDT Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $116 Benzinga

08:14AM EDT SVB Leerink Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $100 Benzinga

07:22AM EDT Barclays Upgrades Neurocrine Biosciences to Overweight, Announces $110 Price Target Benzinga

May 5, 2021

04:32PM EDT Neurocrine Biosciences Q1 Adj. EPS $0.49 Misses $0.51 Estimate, Sales $236.60M Miss $250.63M Estimate Benzinga

04:09PM EDT Neurocrine Biosciences Inc (NBIX) reported earnings for first quarter that dropped from the same period last year. RTTNews

04:07PM EDT Neurocrine Biosciences Q1 GAAP EPS $0.33 Vs $0.39 Last Year RTTNews

04:02PM EDT Neurocrine Biosciences Reports First Quarter 2021 Financial Results PR Newswire

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

04:02PM EDT Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare PR Newswire

May 3, 2021

08:34AM EDT Neurocrine Biosciences Supports Mental Health Month And Tardive Dyskinesia Awareness Week RTTNews

08:31AM EDT Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia PR Newswire

Apr 26, 2021

04:02PM EDT Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides Benzinga

04:01PM EDT Sentia Medical Sciences and Neurocrine Biosciences Enter into GlobeNewswire Inc

10:12AM EDT Mizuho Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $116 Benzinga

Apr 19, 2021

10:52AM EDT Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $125 Benzinga

Apr 16, 2021

09:01AM EDT Neurocrine Biosciences Appoints Johanna Mercier To Its Board RTTNews

09:01AM EDT Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of PR Newswire

Apr 14, 2021

04:01PM EDT Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter PR Newswire

Apr 12, 2021

08:17AM EDT Wedbush Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $112 Benzinga

Apr 8, 2021

04:02PM EDT Neurocrine Biosciences Says Will Present Data From Neurology Portfolio At American Academy Of Neurology's 73rd 2021 Virtual Meeting Benzinga

04:01PM EDT Neurocrine Biosciences to Present Data from its Neurology Portfolio at the PR Newswire

03:59PM EDT FDA's AccessData Site Shows Orphan Drug Designation For Neurocrine Bioscience's Epileptic Encephalopathy Treatment Benzinga

Mar 25, 2021

04:01PM EDT Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day PR Newswire

09:58AM EDT Neurocrine Biosciences, Inc. (NBIX) shares are trading more than 10 percent on Thursday morning trade as the company will be replacing O-I Glass Inc. (OI) in the S&P MidCap 600, effective March 30. The shares have been gaining since yesterday. RTTNews

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 24, 2021

06:36PM EDT Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P PR Newswire

Mar 20, 2021

11:30AM EDT Neurocrine Biosciences To Present New Data Analyses For Crinecerfont In Classic Congenital Adrenal Hyperplasia RTTNews

11:00AM EDT Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults PR Newswire

Mar 9, 2021

04:01PM EST Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare PR Newswire

Mar 2, 2021

11:22AM EST Cantor Fitzgerald Comments On Neurocrine Biosciences Following Phase 2 Data On Co.'s Luvadaxistat: Says, 'No Positive on Negative Symptoms, but Signal in Cogniton Keeps luva' in the Game'; Maintains Overweight Rating, $128 Price Target Benzinga

08:53AM EST Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity Benzinga

07:58AM EST Neurocrine Biosciences (NBIX) said the investigational drug luvadaxistat did not meet primary endpoint in the phase II INTERACT study in adults with negative symptoms of schizophrenia. Luvadaxistat met secondary endpoints of cognitive assessment. RTTNews

07:37AM EST Neurocrine Biosciences Says Luvadaxistat Did Not Meet Primary Endpoint In Phase II INTERACT Study RTTNews

07:35AM EST Neurocrine Biosciences Announces Phase II INTERACT Study Evaluating Luvadaxistat In Cognitive Impairment Associated With Schizophrenia Did Not Meet Primary Endpoint Benzinga

07:31AM EST Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS) PR Newswire

Feb 23, 2021

04:01PM EST Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care PR Newswire

Feb 5, 2021

01:22PM EST Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $119 Benzinga

Feb 4, 2021

04:49PM EST Recap: Neurocrine Biosciences Q4 Earnings Benzinga

04:27PM EST Neurocrine Biosciences Q4 EPS $0.91 Beats $0.54 Estimate, Sales $247.90M Miss $262.40M Estimate Benzinga

04:27PM EST Neurocrine Biosciences Q4 EPS $0.91 May Not Compare To $0.54 Estimate, Sales $247.90M Miss $262.40M Estimate Benzinga

04:06PM EST Neurocrine Biosciences Inc (NBIX) reported a profit for its fourth quarter that increased from the same period last year. RTTNews

04:04PM EST Neurocrine Biosciences Q4 EPS $3.58 Vs. $0.35 Year Ago RTTNews

04:02PM EST Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial PR Newswire

08:35AM EST Earnings Scheduled For February 4, 2021 Benzinga

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Feb 3, 2021

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

Feb 2, 2021

04:10PM EST Voyager Therapeutics Provided An Update On Its NBIb-1817 (VY-AADC) Gene Therapy Program Benzinga

04:01PM EST Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of the Parkinsons disease portion of the collaboration agreement, effective August 2, 2021. The Friedreichs ataxia program and two discovery programs that are also part of the agreement are not impacted and remain under active collaboration. GlobeNewswire Inc

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2021 Benzinga

06:06AM EST Raymond James Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of $163 Benzinga

Jan 30, 2021

01:19PM EST The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga

Jan 20, 2021

04:01PM EST Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter PR Newswire

Jan 8, 2021

07:41AM EST Neurocrine Biosciences Preliminary Full-Year INGREZZA Net RTTNews

07:34AM EST Neurocrine Biosciences Preliminary 2020 INGREZZA Net Product Sales And TRx Both Up 32% To About $993 Mln RTTNews

07:33AM EST Neurocrine Biosciences Sees Q4 INGREZZA Sales of ~$240M, FY20 Sales of ~$993M Benzinga

07:30AM EST Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 PR Newswire

Jan 4, 2021

04:01PM EST Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare PR Newswire

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

04:18PM EST Voyager Therapeutics Reports FDA Notified Neurocrine Biosciences It Placed Clinical Hold On RESTORE-1 Trial Of VY-AADC Benzinga

04:17PM EST Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene GlobeNewswire Inc

Dec 16, 2020

12:59PM EST Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $121 Benzinga

Nov 19, 2020

09:03AM EST Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire

08:02AM EST Neurocrine Biosciences Announces Repurchase of Convertible Notes PR Newswire

Nov 12, 2020

10:09AM EST Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $122 Benzinga

Nov 10, 2020

09:30AM EST Credit Suisse Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $90 Benzinga

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

08:16AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

07:12AM EST 07:11 Tuesday, November 10, 2020William Blair (RTTNews) - William Blair Reiterates Neurocrine Biosciences Inc (NBIX) At Outperform RTTNews

Nov 9, 2020

04:54PM EST Recap: Neurocrine Biosciences Q3 Earnings Benzinga

04:12PM EST Neurocrine Biosciences Q3 EPS $0.97 Up From $0.90 YoY, Sales $258.50M Miss $283.04M Estimate Benzinga

04:04PM EST Neurocrine Biosciences Q3 Loss/share $0.62 Vs. Profit $0.56 Year Ago RTTNews

04:02PM EST Neurocrine Biosciences Reports Third Quarter 2020 Financial Results PR Newswire

09:01AM EST Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 6, 2020

10:18AM EST Preview: Neurocrine Biosciences's Earnings Benzinga

Oct 8, 2020

10:02AM EDT Neurocrine Biosciences, Xenon Pharmaceuticals Provide Regulatory Update On Ongoing Collaboration To Develop First-In-Class Treatment For Epilepsy; Says FDA Grants Rare Pediatric Disease Designation For NBI-921352 For Treatment Of SCN8A-DEE Benzinga

08:21AM EDT Neurocrine Biosciences And Xenon Pharmaceuticals Report FDA Is Requesting Additional Non-clinical Data To Support Dose Justification In Pediatric Study Of NBI-921352 Benzinga

08:00AM EDT U.S. Food and Drug Administration(FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients GlobeNewswire Inc

Oct 7, 2020

06:51AM EDT Neurocrine Biosciences And Me2/Orchestra Team Up With Mental Health Advocacy Community To Launch Monumental Moments RTTNews

06:45AM EDT Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments(tm), an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic PR Newswire

Oct 6, 2020

04:01PM EDT Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter PR Newswire

Sep 30, 2020

09:35AM EDT Benzinga's Top Upgrades, Downgrades For September 30, 2020 Benzinga

07:28AM EDT Benchmark Initiates Coverage On Neurocrine Biosciences with Hold Rating Benzinga

Sep 28, 2020

04:04PM EDT Neurocrine Biosciences To Present New Data Analyses Of ONGENTYS In Patients With Parkinson's Disease RTTNews

04:02PM EDT Neurocrine Biosciences To Present New Data Analyses Of Once-Daily ONGENTYS In Patients With Parkingson's Disease At The American Neurological Association 2020 Virtual Meeting Benzinga

04:01PM EDT (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting PR Newswire

Sep 14, 2020

08:58AM EDT Neurocrine Reports Once-Daily ONGENTYS Available In US As Add-On Treatment For Patients With Parkinson's Disease RTTNews

08:45AM EDT Neurocrine Biosciences Report Once-Daily ONGENTYS Now Available In US As Add-On Treatment For Patients With Parkinson's Disease Experiencing 'Off' Episodes Benzinga

08:45AM EDT Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes PR Newswire

06:53AM EDT 06:52 Monday, September 14, 2020William Blair (RTTNews) - William Blair Reiterates Neurocrine Biosciences Inc (NBIX) At Outperform RTTNews

Sep 11, 2020

11:37AM EDT Neurocrine Biosciences Highlights Presentation Of New Data Showing Efficacy Of FDA-Approved Once-Daily ONGENTYS (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020 Benzinga

11:37AM EDT -- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 -- GlobeNewswire Inc

11:35AM EDT FDA-Approved Once-Daily ONGENTYS(r) (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020 PR Newswire

11:34AM EDT Neurocrine Biosciences, Voyager Therapeutics Highlight Presentation Of New Long-Term, 3-Year Data Showing 1-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease Benzinga

11:33AM EDT Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease PR Newswire

Sep 8, 2020

04:01PM EDT Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global PR Newswire

Sep 3, 2020

04:07PM EDT for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings PR Newswire

Sep 2, 2020

04:01PM EDT Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual PR Newswire

Aug 28, 2020

10:11AM EDT Looking Into Neurocrine Biosciences's Return On Capital Employed Benzinga

Aug 21, 2020

07:49AM EDT Cramer Gives His Opinion On Yeti, Boeing And More Benzinga

Aug 4, 2020

10:16AM EDT Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $145 Benzinga

09:35AM EDT Benzinga's Top Upgrades, Downgrades For August 4, 2020 Benzinga

08:48AM EDT Credit Suisse Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $126 Benzinga

08:35AM EDT Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $146 Benzinga

07:23AM EDT Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $132 Benzinga

07:01AM EDT Cantor Fitzgerald Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $161 Benzinga

06:09AM EDT HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Raises Price Target to $140 Benzinga

05:36AM EDT JP Morgan Downgrades Neurocrine Biosciences to Neutral, Announces $136 Price Target Benzinga

05:03AM EDT SVB Leerink Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $120 Benzinga

Aug 3, 2020

04:05PM EDT Neurocrine Biosciences Q2 EPS $0.81 Vs. $0.54 Year Ago RTTNews

04:04PM EDT Neurocrine Biosciences Q2 Adj. EPS $1.42 Beats $0.73 Estimate, Sales $302.40M Beat $260.34M Estimate Benzinga

04:04PM EDT Neurocrine Biosciences Inc (NBIX) reported a profit for its second quarter that advanced from the same period last year. RTTNews

04:01PM EDT Neurocrine Biosciences Reports Second Quarter 2020 Financial Results PR Newswire

04:13AM EDT Earnings Scheduled For August 3, 2020 Benzinga

Jul 30, 2020

04:01PM EDT Neurocrine Biosciences to Participate at the William Blair Biotech Focus PR Newswire

Jul 23, 2020

08:56AM EDT Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $127 Benzinga

Jul 20, 2020

08:14AM EDT Credit Suisse Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $135 Benzinga

Jul 15, 2020

10:45AM EDT Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $149 Benzinga

Jul 13, 2020

04:19PM EDT Neurocrine Biosciences 8-K Shows Co. Set Wholesale Acquisition Cost For 30-Count Bottle Of ONGENTYS 25 mg, 50 mg Capsules At $590; Co. Sees Commercial Launch Later In 2020 Benzinga

04:01PM EDT Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter PR Newswire